

10/61/60  
JC973 U.S. PTO10/61/60  
JC973 U.S. PTO

# UTILITY PATENT APPLICATION TRANSMITTAL

(Only for new nonprovisional applications under 37 C.F.R. 1.53(b))

Attorney Docket No. 16517.257

First Inventor Sherri M. BROWN, et al.

Title Nucleic Acid Molecules and Other Molecules Associated with the Gibberellin Pathway

Express Mail Label No.

**APPLICATION ELEMENTS**

See MPEP chapter 600 concerning utility patent application contents.

1.  Fee Transmittal Form (e.g., PTO/SB/17)  
*(Submit an original and a duplicate for fee processing)*

2.  Applicant claims small entity status.  
See 37 CFR 1.27.

3.  Specification [Total Pages 219]  
*(preferred arrangement set forth below)*  
 - Descriptive title of the Invention  
 - Cross References to Related Applications  
 - Statement Regarding Fed sponsored R & D  
 - Reference to sequence listing, a table, or a computer program listing appendix  
 - Background of the Invention  
 - Brief Summary of the Invention  
 - Brief Description of the Drawings (*if filed*)  
 - Detailed Description  
 - Claim(s)  
 - Abstract of the Disclosure

4.  Drawing(s) (35 U.S.C.113) [Total Sheets 1 ]

5. Oath or Declaration [Total Pages 15]  
 a.  Newly executed (original or copy)  
 b.  Copy from a prior application (37 CFR 1.63 (d))  
*(for a continuation/divisional with Box 18 completed)*  
 i.  **DELETION OF INVENTOR(S)**  
 Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b).

6.  Application Data Sheet. See 37 CFR 1.76

**ADDRESS TO:** Assistant Commissioner for Patents  
Box Patent Application  
Washington, DC 20231

7.  CD-ROM or CD-R in duplicate, large table or Computer Program (*Appendix*)

8. Nucleotide and/or Amino Acid Sequence Submission (*if applicable, all necessary*)  
 a.  Computer Readable Form (CRF)  
 b. Specification Sequence Listing on:  
 i.  CD-ROM or CD-R (2 copies); or  
 ii.  paper  
 c.  Statements verifying identity of above copies

**ACCOMPANYING APPLICATIONS PARTS**

9.  Assignment Papers (cover sheet & document(s))

10.  37 C.F.R. §3.73(b) Statement  Power of Attorney  
*(when there is an assignee)*

11.  English Translation Document (*if applicable*)

12.  Information Disclosure Statement (IDS)/PTO-1449  Copies of IDS Citations

13.  Preliminary Amendment

14.  Return Receipt Postcard (MPEP 503)  
*(Should be specifically itemized)*

15.  Certified Copy of Priority Document(s)  
*(if foreign priority is claimed)*

16.  Request and Certification under 35 U.S.C. 122 (b)(2)(B)(i). Applicant must attach form PTO/SB/35 or its equivalent.

17.  Other: \_\_\_\_\_

18. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76:

 Continuation     Divisional     Continuation-in-part (CIP)  
 Prior application information: Examiner ZEMAN, M.

of prior application No: 09 / 252,974

Group / Art Unit: 1631

For CONTINUATION or DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.


**17. CORRESPONDENCE ADDRESS**

28381

 Customer Number or Bar Code Label      or  Correspondence address below

(Insert Customer No. or Attach bar code label here)

Name	David R. Marsh June E. Cohan				
Address	ARNOLD & PORTER 555 12th Street, N.W.				
City	Washington	State	D.C.	Zip Code	20004-1206
Country	USA	Telephone	202-942-5000		Fax 202-942-5999

Name (Print/Type)	David R. Marsh / June E. Cohan	Registration No. (Attorney/Agent)	41,408 / 43,741
Signature			Date Sept. 19, 2001

Burden Hour Statement This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.

# ARNOLD & PORTER

202.942.5000  
202.942.5999 Fax

555 Twelfth Street, NW  
Washington, DC 20004-1206

September 19, 2001

## *Box Patent Application*



Commissioner for Patents  
Washington, D.C. 20231



Re: U.S. Continuation Application  
Appl. No.: To Be Assigned  
Filed: Herewith  
For: Nucleic Acid Molecules and Other Molecules  
Associated with the Gibberellin Pathway  
Inventors: Sherri M. BROWN, *et al.*  
Atty. Docket: 16517.257

Sir:

The following documents are forwarded herewith for appropriate action by the U.S.  
Patent and Trademark Office.

1. Utility Patent Application Transmittal (PTO/SB/05);
2. U.S. Non-Provisional Application entitled:

### **Nucleic Acid Molecules and Other Molecules Associated with the Gibberellin Pathway**

and naming as inventors:

Sherri M. Brown, Gregory R. Heck and Jingdong Liu;

the application consisting of:

- a. A specification containing:
  - (i) 214 pages of a description prior to the claims;
  - (ii) 4 pages of claims (9 claims); and
  - (iii) a one (1) page abstract;
3. a Statement Regarding Sequence Submission;

4. the sequence listing in computer readable form (*i.e.*, CRF) (1 diskette);
5. a paper copy of the sequence listing (34 pages);
6. a Request and Certification Under 35 U.S.C. 122(b)(2)(B)(i) (PTO/SB/35);
7. Preliminary Amendment;
8. check No. 139309 in the amount of \$710 to cover the basic continuation filing fee; and
9. two (2) return postcards.


Submitted herewith is a sequence listing and a sequence listing in Computer Readable Form (CRF) on diskette, in compliance with 37 C.F.R. §§ 1.52(e), 1.77, and 1.823.

It is respectfully requested that, of the two attached postcards, one be stamped with the filing date of these documents and returned to our courier, and the other, prepaid postcard, be stamped with the filing date and unofficial application number and returned as soon as possible.

This application is a continuation of prior application no. 09/252,974 filed on February 19, 1999.

Applicants do not believe that any fees other than the basic filing fee (\$710) are due in conjunction with this filing. However, should any additional fees be required, the Patent and Trademark Office is authorized to charge any additional fees or credit any overpayment to Arnold and Porter deposit account 50-1824 referencing matter number 16517.257. This letter is submitted in duplicate.

Respectfully submitted,



David R. Marsh (Reg. No. 41,408)  
June E. Cohan (Reg. No. 43,741)

Enclosures


**REQUEST AND CERTIFICATION  
UNDER  
35 U.S.C. 122(b)(2)(B)(i)**

First Named Inventor		Sherri M. BROWN, et al.
Title	Nucleic Acid Molecules and Other Molecules Associated with the Gibberellin Pathway	
Atty Docket Number	16517.257	

I hereby certify that the invention disclosed in the attached application **has not and will not be** the subject of an application filed in another country, or under a multilateral agreement, that requires publication at eighteen months after filing. I hereby request that the attached application not be published under 35 U.S.C. 122(b).

September 19, 2001

Date



Signature

David R. Marsh (Reg. No 41,408)  
June E. Cohan (Reg. No. 43,741)

Typed or printed name

This request must be signed in compliance with 37 CFR 1.33(b) and submitted with the application **upon filing**.

Applicant may rescind this nonpublication request at any time. If applicant rescinds a request that an application not be published under 35 U.S.C. 122(b), the application will be scheduled for publication at eighteen months from the earliest claimed filing date for which a benefit is claimed.

If applicant subsequently files an application directed to the invention disclosed in the attached application in another country, or under a multilateral international agreement, that requires publication of applications eighteen months after filing, the applicant **must** notify the United States Patent and Trademark Office of such filing within forty-five (45) days after the date of the filing of such foreign or international application. **Failure to do so will result in abandonment of this application (35 U.S.C. 122(b)(2)(B)(iii)).**

Burden Hour Statement. This collection of information is required by 37 CFR 1.213(a). The information is used by the public to request that an application not be published under 35 U.S.C. 122(b) (and the PTO to process that request). Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This form is estimated to take 6 minutes to complete. This time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Continuation application of:

Sherri M. BROWN, et al.

Art Unit: To be assigned

Appln. No.: To Be Assigned

Examiner: To be assigned

Filed: Herewith

Atty. Docket: 16517.257

For: Nucleic Acid Molecules and Other  
Molecules Associated with the  
Gibberellin Pathway


**Statement Regarding Sequence Submission**

Commissioner for Patents  
Washington, DC 20231

Sir:

In accordance with 37 C.F.R. § 1.821(f), the paper copy of the Sequence Listing and the computer-readable copy of the Sequence Listing submitted herewith in the above-mentioned application are the same.

Respectfully submitted,



J. E. C.  
David R. Marsh (Reg. No. 41,408)  
June E. Cohan (Reg. No. 43,741)

Date: September 19, 2001

Arnold & Porter  
555 12<sup>th</sup> Street, N.W.  
Washington, D.C. 20004  
(202) 942-5000 telephone  
(202) 942-5999 facsimile